Prevail Therapeutics

YTD

ALL

Why Robinhood?

You can watch PRVL and buy or sell other stocks, ETFs, and their options commission-free!

About PRVL

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

CEO

Franz F. Hefti, PhD

CEOFranz F. Hefti, PhD

Employees

—

Employees—

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2017

Founded2017

Employees

—

Employees—

PRVL Key Statistics

Market cap

787.70M

Market cap787.70M

Price-Earnings ratio

-10.03

Price-Earnings ratio-10.03

Dividend yield

—

Dividend yield—

Average volume

1.19M

Average volume1.19M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$23.35

52 Week high$23.35

52 Week low

$9.02

52 Week low$9.02

People also own

Based on the portfolios of people who own PRVL. This list is generated using Robinhood data, and it’s not a recommendation.

Virgin Galactic Holdings